期刊文献+

IL-2联合5-氟尿嘧啶治疗晚期肾癌50例疗效观察 被引量:2

The Efficacy of IL-2 Combined with 5-FU in Treatment of 50 Patients with Advanced Renal Cell Carcinoma
下载PDF
导出
摘要 目的比较晚期肾癌免疫化疗和单纯免疫治疗的效果,指导临床治疗方法的选择.方法 50例晚期肾癌患者随机分为两组,每组25例,治疗组患者应用IL-2联合5氟尿嘧啶(5-Fu)治疗,所有患者均接受连续4个周期治疗;对照组单用IL-2治疗4个周期;根据WHO抗肿瘤药物客观疗效标准进行疗效评定.结果 50例患者均按实验设计完成实验,治疗组完全缓解5例,部分缓解11例,总有效率为64%;对照组完全缓解2例,部分缓解6例,总有效率为30%(6/25),两组差异具有统计学意义(P<0.05).结论小剂量IL-2联合5-Fu是治疗晚期肾癌的较好手段. Objective To compare the efficacy between chemotherapy combined with immunotherapy and simple immunotherapy for advanced renal cell carcinoma,in order to select the better treatment.Methods 50 patients with advanced renal cell carcinoma were randomly divided into two groups,25 patients in each group.Patents in the treatment group was treated with IL-2 combined with 5-fluorouracil(5-Fu)for 4 cycles,and patients in the control group was treated with only IL-2 for 4 cycles.According to the objective standard of anticancer drug efficacy in WHO,the efficacy was evaluated.Results According to experimental design,the treatment was completed in all 50 patients.In the treatment group,5 patients got complete remission,and 11 patients got partial remission,the total effective rate was 64%(15/25);in the control group,2 patients got complete remission,and 6 patiens got partial remission,the effective rate was 30%,there was a statistically significant difference in the total effective rate between the two groups(P0.05).Conclusion Low dose of IL-2 combined with 5-Fu is a good means for the treatment of advanced renal cell carcinoma.
出处 《昆明医学院学报》 2010年第12期93-95,共3页 Journal of Kunming Medical College
关键词 肾癌 免疫化疗 IL-2 5-氟尿嘧啶 Advanced renal cell carcinoma Immune chemotherapy IL-2 5-fluorouracil
  • 相关文献

参考文献8

  • 1TONG T Q,ROHDE D,PETER S.Progress in the management of advanced renal cell carcinoma (RCC)[J].Aktuelle Urol,2010,41(1):57-60.
  • 2FYFE G,FISHER R I,ROSENBERG S A,et al.Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy[J].J Clin Oncol,1995,13(3):688-696.
  • 3KIRKALI Z,TUZEL E.Systemic therapy of kidney cancer:tyrosine kinase inhibitors,antiangiogenesis or IL-2[J].Future Oncol,2009,5(6):871-888.
  • 4GOLLOB J,RICHMOND T,JONES J,et al.Phase Ⅱ trial of s orafenib plus interferon-Mpha 2b(IFN-α 2b)as firstor secondline therapy in patients(P ts) with metastatic renal cell cancer(RCC)[J].J Clin Oncol,2006,24(1):453-458.
  • 5MOTZER R J,HUTS ON T E,TOMCZAK P,et al.Sunitinib versug interfeton alfa in metastatic renal-cell carcinoma[J].N Engl J Med,2007,35(6):115-124.
  • 6HARSHMAN L C,KUOC J,WONG B Y,et al.Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma[J].Cancer Invest,2009,27(8):851-856.
  • 7CELLA D,MICHAELSON M D.Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase Ⅲ trial:final results and geographical analysis[J].Br J Cancer,2010,102(4):658-664.
  • 8ZENG H,LI X,YAO J,et al.Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinih[J].Urol Int,2009,83(4):482-485.

同被引文献52

  • 1石明,韩平,曹贵华,魏强,杨宇如.肾癌术后应用α-干扰素的疗效分析[J].华西医学,2006,21(2):288-289. 被引量:6
  • 2那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南(2014版)[M].北京:人民卫生出版社,2014:528.
  • 3International Agency for research on cancer: GLOBOCAN 2012: estimated cancer indence, mortality and prevalence wordwiade in 2012[DB/MTJ. http s./Zglobocan. iarc. fr/Pages/fact_sheets_population. aspx,2015 - 3 -1.
  • 4National Cacer Instute , SEER cancer statistics 2014 [DB/MT]. http://seer. cancer. grv/statfacts/htmVkidrp. html,2015 -3-1.
  • 5Ferlay J , Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006 [J]. Annals of oncology , 2007,18 (3) ;581 - 592.
  • 6Gupta S, Spiess PE. The prospects of pazopanib in advance reanl cell carcinoma [J] . Ther Adv Urol ,2013,5 :223 - 232.
  • 7Bukowski RM. Natural history and theraph of metastatic reanl cell carcinoma: The role of interleukin - 2 [J] . Cancer, 1997 ,80 : 1198 -1220.
  • 8Gunduz S, Mutiu H, Uysal M, et al. Prognostic value of hematologic parameters in patients metastatic reanl cell carcinoma using tyrosine kinase inhibitors[J]. Asian Pac J Cancer Prev,2014,15(8): 3801 -3804.
  • 9Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa - 2b compared with interferon alfa - 2b alone for metastatic reanl cell carcinoma[J]. N Engl J Med,2001, 345(23) :1655 -1659.
  • 10Mikisch GH, Garin A. Van PH, et al. Radical nephrectomy puls interferon alfa alone in metastatic reanl cell carcinoma: a randomized trial] L]. Lancet,2011 ,358 :966 -970.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部